Image Place holder

Khaldoun Almhanna, MD, MPH

Specialty: Medical Oncology
Program: Gastrointestinal Oncology

Call 1-888-MOFFITT

or call 1-888-MOFFITT


Dr. Khaldoun Almhanna is a medical oncologist of the Department of Gastrointestinal Oncology at Moffitt Cancer Center.  He is an associate professor of oncology at the University of South Florida College of Medicine Dr. Almhanna’s research and clinical interests include phase I and II trials using personalized targeted therapy for gastrointestinal cancers, in particular, esophageal and gastric cancer. Dr. Almhanna received his medical degree from Damascus University School of Medicine in Syria and served an internal medicine internship at Damascus University Hospital.  He went on to receive a master’s of public health degree from Case Western Reserve University in Cleveland, OH, followed by an internal medicine residency at Oakwood Hospital and Medical Center in Dearborn, MI.  Dr. Almhanna completed a hematology/oncology fellowship at the Cleveland Clinic. Before coming to Moffitt in 2010, Dr. Almhanna was an assistant professor of oncology at Wayne University in Detroit, MI.  He is widely published and serves as an editorial reviewer for Clinical Colorectal Cancer, Head and Neck Cancer and Disease of the Esophagus.  Dr. Almhanna is a member of the American Society of Hematology and American Society of Clinical Oncology. Dr. Almhanna was voted Doctor of the Year in Michigan in 2009 and Doctor of the Year in Tampa in 2011.  He is fluent in English, Arabic and French.  

Education & Training

Board Certification:

  • Medical Oncology


  • Cleveland Clinic - Hematology-Oncology


  • Oakwood Hospital and Medical Center - Internal Medicine

Medical School:

  • Damascus University - MD
Participating Trials

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)
Condition: Multiple
Intervention: Not Applicable; Pembrolizumab (Keytruda)

A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*0401 Positive Subjects with Advanced Cancers
Condition: Multiple
Intervention: Aldesleukin (Interleukin-2); IL-2 (Interleukin-2); Interleukin-2; KITE-718; MESNA; Proleukin (Interleukin-2); cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE)Compound KPT-8602 in Patients with Relapsed/Refractory Cancer Indications
Condition: Multiple
Intervention: Abiraterone acetate; Dexamethasone; KPT-8602; Zytiga (Abiraterone acetate)

A Phase I/II Study of Pembrolizumab in Combination with Ibrutinib for Advanced, Refractory Colorectal Cancers
Condition: Gastrointestinal Tumor
Intervention: 748645 (Ibrutinib); Ibrutinib (Imbruvica); PCI-32765 (Ibrutinib); Pembrolizumab (Keytruda)

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).


  • Saeed NA, Mellon EA, Meredith KL, Hoffe SE, Shridhar R, Frakes J, Fontaine JP, Pimiento JM, Kothari N, Almhanna K. Adjuvant chemotherapy and outcomes in esophageal carcinoma. J Gastrointest Oncol. 2017 Oct;8(5):816-824. Pubmedid: 29184685. Pmcid: PMC5674263.
  • Murimwa GZ, Venkat PS, Jin W, Leuthold S, Latifi K, Almhanna K, Pimiento JM, Fontaine JP, Hoffe SE, Frakes JM. Impact of sarcopenia on outcomes of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation followed by surgery. J Gastrointest Oncol. 2017 Oct;8(5):808-815. Pubmedid: 29184684. Pmcid: PMC5674260.
  • Almhanna K, Wright D, Mercade TM, Van Laethem JL, Gracian AC, Guillen-Ponce C, Faris J, Lopez CM, Hubner RA, Bendell J, Bols A, Feliu J, Starling N, Enzinger P, Mahalingham D, Messersmith W, Yang H, Fasanmade A, Danaee H, Kalebic T. A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. Invest New Drugs. 2017 Oct;35(5):634-641. Pubmedid: 28527133.
  • Saeed N, Shridhar R, Almhanna K, Hoffe S, Chuong M, Meredith K. CT-based assessment of visceral adiposity and outcomes for esophageal adenocarcinoma. J Gastrointest Oncol. 2017 Oct;8(5):833-841. Pubmedid: 29184687. Pmcid: PMC5674266.
  • Almhanna K, Antonia S. PD-L1 Antibodies for EBV-Positive Gastric Cancer, Going Beyond PD-L1 Expression and Microsatellite Instability. J Natl Cancer Inst. 2017 Nov. Pubmedid: 29155933.
  • Salem AI, Thau MR, Strom TJ, Abbott AM, Saeed N, Almhanna K, Hoffe SE, Shridhar R, Karl RC, Meredith KL. Effect of body mass index on operative outcome after robotic-assisted Ivor-Lewis esophagectomy: retrospective analysis of 129 cases at a single high-volume tertiary care center. Dis Esophagus. 2017 Jan;30(1):1-7. Pubmedid: 27149640.
  • Elimova E, Janjigian YY, Mulcahy M, Catenacci DV, Blum MA, Almhanna K, Hecht JR, Ajani JA. It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma. J Clin Oncol. 2017 Feb;35(4):475-477. Pubmedid: 28129519.
  • Almhanna K, Prithviraj GK, Veiby P, Kalebic T. Antibody-drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies. Pharmacol Ther. 2017 Feb;170:8-13. Pubmedid: 27765652.
  • Luu C, Thapa R, Woo K, Coppola D, Almhanna K, Pimiento JM, Chen DT, Marquez DD, Hodul PJ. Does histology really influence gastric cancer prognosis?. J Gastrointest Oncol. 2017 Dec;8(6):1026-1036. Pubmedid: 29299363. Pmcid: PMC5750182.
  • Luu C, Amaral M, Klapman J, Harris C, Almhanna K, Hoffe S, Frakes J, Pimiento JM, Fontaine JP. Endoscopic ultrasound staging for early esophageal cancer: Are we denying patients neoadjuvant chemo-radiation?. World J Gastroenterol. 2017 Dec;23(46):8193-8199. Pubmedid: 29290655. Pmcid: PMC5739925.
  • Blackham AU, H Naqvi SM, Schell MJ, Jin W, Gangi A, Almhanna K, Fontaine JP, Hoffe SE, Frakes J, Venkat P, Pimiento JM. Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer. J Surg Oncol. 2017 Aug. Pubmedid: 28833197.
  • Almhanna K, Miron ML, Wright D, Gracian AC, Hubner RA, Van Laethem JL, López CM, Alsina M, Muñoz FL, Bendell J, Firdaus I, Messersmith W, Ye Z, Fasanmade AA, Danaee H, Kalebic T. Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C. Invest New Drugs. 2017 Apr;35(2):235-241. Pubmedid: 28188407.
  • Almhanna K, Kalebic T, Cruz C, Faris JE, Ryan DP, Jung JA, Wyant T, Fasanmade A, Messersmith WA, Rodon J. Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies. Clin Cancer Res. 2016 Oct;22(20):5049-5057. Pubmedid: 27178743.
  • Almhanna K, Rosa M, Henderson-Jackson E, Jiang K, Shamekh R, Sayegh Z, Malafa MP, Coppola D. Her-2 Expression in Gastroesophageal Intestinal Metaplasia, Dysplasia, and Adenocarcinoma. Appl Immunohistochem Mol Morphol. 2016 Oct;24(9):633-638. Pubmedid: 26186253.
  • Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, Denlinger CS, Fanta P, Farjah F, Fuchs CS, Gerdes H, Gibson M, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Korn WM, Leong S, Linn C, Lockhart AC, Ly QP, Mulcahy MF, Orringer MB, Perry KA, Poultsides GA, Scott WJ, Strong VE, Washington MK, Weksler B, Willett CG, Wright CD, Zelman D, McMillian N, Sundar H. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2016 Oct;14(10):1286-1312. Pubmedid: 27697982.
  • Almhanna K, Weber J, Shridhar R, Hoffe S, Strosberg J, Meredith K. Determining the optimal number of lymph nodes harvested during esophagectomy. J Gastrointest Oncol. 2016 Jun;7(3):387-394. Pubmedid: 27284471. Pmcid: PMC4880760.
  • Kucera S, Barthel J, Klapman J, Shridhar R, Hoffe S, Harris C, Almhanna K, Meredith K. Small caliber covered self-expanding metal stents in the management of malignant dysphagia. J Gastrointest Oncol. 2016 Jun;7(3):411-419. Pubmedid: 27284474. Pmcid: PMC4880758.
  • Kim R, Prithviraj GK, Shridhar R, Hoffe SE, Jiang K, Zhao X, Chen DT, Almhanna K, Strosberg J, Campos T, Shibata D. Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. Radiother Oncol. 2016 Feb;118(2):382-386. Pubmedid: 26861740.
  • Greenleaf EK, Kulaylat AN, Hollenbeak CS, Almhanna K, Wong J. Timing of Adjuvant Chemotherapy and Impact on Survival for Resected Gastric Cancer. Ann Surg Oncol. 2016 Dec;23(13):4203-4213. Pubmedid: 27459982.
  • Kothari N, Mellon E, Hoffe SE, Frakes J, Shridhar R, Pimiento J, Meredith K, Tran ND, Saeed N, Almhanna K. Outcomes in patients with brain metastasis from esophageal carcinoma. J Gastrointest Oncol. 2016 Aug;7(4):562-569. Pubmedid: 27563446. Pmcid: PMC4963374.
  • Saeed N, Shridhar R, Hoffe S, Almhanna K, Meredith KL. AKT expression is associated with degree of pathologic response in adenocarcinoma of the esophagus treated with neoadjuvant therapy. J Gastrointest Oncol. 2016 Apr;7(2):158-165. Pubmedid: 27034781. Pmcid: PMC4783740.
  • Shridhar R, Abbott AM, Doepker M, Hoffe SE, Almhanna K, Meredith KL. Perioperative outcomes associated with robotic Ivor Lewis esophagectomy in patient's undergoing neoadjuvant chemoradiotherapy. J Gastrointest Oncol. 2016 Apr;7(2):206-212. Pubmedid: 27034787. Pmcid: PMC4783744.
  • Abbott AM, Kim R, Hoffe SE, Arslan B, Biebel B, Choi J, El-Haddad G, Kis B, Sweeney J, Meredith KL, Almhanna K, Strosberg J, Shibata D, Fulp WJ, Shridhar R. Outcomes of Therasphere Radioembolization for Colorectal Metastases. Clin Colorectal Cancer. 2015 Sep;14(3):146-153. Pubmedid: 25795047.
  • Mahipal A, Shibata D, Siegel E, Springett G, Almhanna K, Fulp W, Williams-Elson I, Kim R. Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies. Invest New Drugs. 2015 Oct;33(5):1093-1099. Pubmedid: 26275531.
  • Prithviraj GK, Baksh K, Fulp W, Meredith K, Hoffe S, Shridhar R, Almhanna K. Carboplatin and paclitaxel as first-line treatment of unresectable or metastatic esophageal or gastric cancer. Dis Esophagus. 2015 Nov;28(8):782-787. Pubmedid: 25155802.
  • Blackham AU, Yue B, Almhanna K, Saeed N, Fontaine JP, Hoffe S, Shridhar R, Frakes J, Coppola D, Pimiento JM. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response. J Surg Oncol. 2015 Nov;112(6):597-602. Pubmedid: 26394724.
  • Almhanna K, Hoffe S, Strosberg J, Dinwoodie W, Meredith K, Shridhar R. Concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil (5-FU) and cisplatin for locally advanced resectable esophageal cancer. J Gastrointest Oncol. 2015 Feb;6(1):39-44. Pubmedid: 25642336. Pmcid: PMC4294830.
  • Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Besh S, Chao J, Das P, Denlinger C, Fanta P, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Jasperson K, Keswani RN, Kleinberg LR, Korn WM, Leong S, Lockhart AC, Mulcahy MF, Orringer MB, Posey JA, Poultsides GA, Sasson AR, Scott WJ, Strong VE, Varghese TK, Washington MK, Willett CG, Wright CD, Zelman D, McMillian N, Sundar H. Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Ne. 2015 Feb;13(2):194-227. Pubmedid: 25691612.
  • Almhanna K, Hoffe S. Esophageal cancer 2015, more questions than answers. J Gastrointest Oncol. 2015 Feb;6(1):1-2. Pubmedid: 25642332. Pmcid: PMC4294825.
  • Abbott A, Shridhar R, Hoffe S, Almhanna K, Doepker M, Saeed N, Meredith K. Robotic assisted Ivor Lewis esophagectomy in the elderly patient. J Gastrointest Oncol. 2015 Feb;6(1):31-38. Pubmedid: 25642335. Pmcid: PMC4294822.
  • Kothari N, Almhanna K. Current status of novel agents in advanced gastroesophageal adenocarcinoma. J Gastrointest Oncol. 2015 Feb;6(1):60-74. Pubmedid: 25642339. Pmcid: PMC4294823.
  • Baksh K, Prithviraj G, Kim Y, Hoffe S, Shridhar R, Coppola D, Centeno B, Pimiento J, Meredith K, Almhanna K. Correlation Between Standardized Uptake Value in Preneoadjuvant and Postneoadjuvant Chemoradiotherapy and Tumor Regression Grade in Patients With Locally Advanced Esophageal Cancer. Am J Clin Oncol. 2015 Dec. Pubmedid: 26703814.
  • Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Brit J Cancer. 2014 Nov;111(10):1932-1944. Pubmedid: 25290091. Pmcid: PMC4229637.
  • Shridhar R, Freilich J, Hoffe SE, Almhanna K, Fulp WJ, Yue B, Karl RC, Meredith K. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus. Ann Surg Oncol. 2014 Nov;21(12):3744-3750. Pubmedid: 24854492.
  • Wong J, Rahman S, Saeed N, Lin HY, Almhanna K, Shridhar R, Hoffe S, Meredith KL. Effect of body mass index in patients undergoing resection for gastric cancer: a single center US experience. J Gastrointest Surg. 2014 Mar;18(3):505-511. Pubmedid: 24443204.
  • Fernandez DC, Hoffe SE, Barthel JS, Vignesh S, Klapman JB, Harris C, Almhanna K, Biagioli MC, Meredith KL, Feygelman V, Rao NG, Shridhar R. Stability of endoscopic ultrasound-guided fiducial marker placement for esophageal cancer target delineation and image-guided radiation therapy. Pract Radiat Oncol. 2014 Mar;3(1):32-39. Pubmedid: 24674261.
  • Wong J, Weber J, Almhanna K, Hoffe S, Shridhar R, Karl R, Meredith KL. Extent of lymphadenectomy does not predict survival in patients treated with primary esophagectomy. J Gastrointest Surg. 2013 Sep;17(9):1562-1568. Pubmedid: 23818125.
  • Shridhar R, Hoffe SE, Almhanna K, Weber JM, Chuong MD, Karl RC, Meredith K. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy. Ann Surg Oncol. 2013 Sep;20(9):3038-3043. Pubmedid: 23625142.
  • Almhanna K, Cubitt CL, Zhang S, Kazim S, Husain K, Sullivan D, Sebti S, Malafa M. MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines. Cancer Biol Ther. 2013 Oct;14(10):932-936. Pubmedid: 23917345. Pmcid: PMC3926890.
  • Strosberg J, Weber J, Feldman M, Goldman J, Almhanna K, Kvols L. Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors. Gastrointest Cancer Res. 2013 May;6(3):81-85. Pubmedid: 23936548. Pmcid: PMC3737510.
  • Shridhar R, Almhanna K, Hoffe SE, Fulp W, Weber J, Chuong MD, Meredith KL. Increased survival associated with surgery and radiation therapy in metastatic gastric cancer: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2013 Jun;119(9):1636-1642. Pubmedid: 23361968.
  • Melis M, Weber J, Shridhar R, Hoffe S, Almhanna K, Karl RC, Meredith KL. Body mass index and perioperative complications after oesophagectomy for adenocarcinoma: a systematic database review. BMJ Open. 2013 May;3(5). Pubmedid: 23645908. Pmcid: PMC3646172.
  • Chuong MD, Freilich JM, Hoffe SE, Fulp W, Weber JM, Almhanna K, Dinwoodie W, Rao N, Meredith KL, Shridhar R. Intensity-Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. Gastrointest Cancer Res. 2013 Mar;6(2):39-45. Pubmedid: 23745158. Pmcid: PMC3674462.
  • Wong J, Rahman S, Saeed N, Lin HY, Almhanna K, Shridhar R, Hoffe S, Meredith KL. Prognostic impact of lymph node retrieval and ratio in gastric cancer: a U.S. single center experience. J Gastrointest Surg. 2013 Dec;17(12):2059-2066. Pubmedid: 24129828.
  • Hernandez JM, Dimou F, Weber J, Almhanna K, Hoffe S, Shridhar R, Karl R, Meredith K. Defining the learning curve for robotic-assisted esophagogastrectomy. J Gastrointest Surg. 2013 Aug;17(8):1346-1351. Pubmedid: 23690208.
  • Pimiento JM, Weber J, Hoffe SE, Shridhar R, Almhanna K, Vignesh S, Karl RC, Meredith KL. Outcomes associated with surgery for T4 esophageal cancer. Ann Surg Oncol. 2013 Aug;20(8):2706-2712. Pubmedid: 23504118.
  • Shridhar R, Weber J, Hoffe SE, Almhanna K, Karl R, Meredith K. Adjuvant radiation therapy and lymphadenectomy in esophageal cancer: a SEER database analysis. J Gastrointest Surg. 2013 Aug;17(8):1339-1345. Pubmedid: 23749498.
  • Almhanna K, Meredith KL, Hoffe SE, Shridhar R, Coppola D. Targeting the human epidermal growth factor receptor 2 in esophageal cancer. Cancer Control. 2013 Apr;20(2):111-116. Pubmedid: 23571701.
  • Shridhar R, Almhanna K, Meredith KL, Biagioli MC, Chuong MD, Cruz A, Hoffe SE. Radiation therapy and esophageal cancer. Cancer Control. 2013 Apr;20(2):97-110. Pubmedid: 23571700.
  • Wong JY, Shridhar R, Almhanna K, Hoffe SE, Karl RC, Meredith KL. The impact of body mass index on esophageal cancer. Cancer Control. 2013 Apr;20(2):138-143. Pubmedid: 23571704.
  • Vignesh S, Hoffe SE, Meredith KL, Shridhar R, Almhanna K, Gupta AK. Endoscopic therapy of neoplasia related to Barrett's esophagus and endoscopic palliation of esophageal cancer. Cancer Control. 2013 Apr;20(2):117-129. Pubmedid: 23571702.
  • Almhanna K, Shridhar R, Meredith KL. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: is there a standard of care?. Cancer Control. 2013 Apr;20(2):89-96. Pubmedid: 23571699.
  • Almhanna K. Targeted therapy for gastric adenocarcinoma. Adv Pharmacol. 2012 Sep;65:437-470. Pubmedid: 22959034.
  • Almhanna K, Strosberg JR. Multimodality approach for locally advanced esophageal cancer. World J Gastroenterol. 2012 Oct;18(40):5679-5687. Pubmedid: 23155307. Pmcid: PMC3484335.
  • Dittrick GW, Weber JM, Shridhar R, Hoffe S, Melis M, Almhanna K, Barthel J, McLoughlin J, Karl RC, Meredith KL. Pathologic Nonresponders after Neoadjuvant Chemoradiation for Esophageal Cancer Demonstrate no Survival Benefit Compared with Patients Treated with Primary Esophagectomy. Ann Surg Oncol. 2012 May;19(5):1678-1684. Pubmedid: 22045465.
  • Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, Almhanna K, Kim R, Valone T, Jump H, Sullivan D. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer. 2012 May;48(7):997-1003. Pubmedid: 22445247. Pmcid: PMC4522922.
  • Shridhar R, Hayman T, Hoffe SE, Weber J, Almhanna K, Chuong M, Karl RC, Meredith KL. Body mass index and survival in esophageal adenocarcinoma treated with chemoradiotherapy followed by esophagectomy. J Gastrointest Surg. 2012 Jul;16(7):1296-1302. Pubmedid: 22399271.
  • Almhanna K, El-Rayes B, Sethi S, Dyson G, Heilbrun L, Philip PA, Sarkar F. Association between COX-2 expression and effectiveness of COX-2 inhibitors in a phase II trial in patients with metastatic colorectal adenocarcinoma. Anticancer Res. 2012 Aug;32(8):3559-3563. Pubmedid: 22843946. Pmcid: PMC3807874.
  • Almhanna K, Philip PA. Defining new paradigms for the treatment of pancreatic cancer. CURR TREAT OPTION ON. 2011 Jun;12(2):111-125. Pubmedid: 21461670.
  • Almhanna K, Strosberg J, Malafa M. Targeting AKT protein kinase in gastric cancer. Anticancer Res. 2011 Dec;31(12):4387-4392. Pubmedid: 22199303.
  • Ali S, Almhanna K, Chen W, Philip PA, Sarkar FH. Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am J Transl Res. 2010 Sep;3(1):28-47. Pubmedid: 21139804. Pmcid: PMC2981424.
  • El-Rayes BF, Jasti P, Severson RK, Almhanna K, Philip PA, Shields A, Zalupski M, Heilbrun LK. Impact of race, age, and socioeconomic status on participation in pancreatic cancer clinical trials. Pancreas. 2010 Oct;39(7):967-971. Pubmedid: 20467351.
  • Azmi AS, Philip PA, Almhanna K, Beck FW, Sarkar FH, Mohammad RM. MDM2 inhibitors for pancreatic cancer therapy. Mini Rev Med Chem. 2010 Jun;10(6):518-526. Pubmedid: 20377522.
  • Kim R, Tsao R, Tan A, Byrne M, Almhanna K, Lazaryan A, Elson P, Pelley RJ. A single institution review of adjuvant therapy outcomes for resectable pancreatic adenocarcinoma: outcome and prognostic indicators. J Gastrointest Surg. 2010 Jul;14(7):1159-1169. Pubmedid: 20446118.
  • Almhanna K, Philip PA. Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma. Onco Targets Ther. 2009 Jul;2:261-267. Pubmedid: 20616913. Pmcid: PMC2886319.
  • Almhanna K, Wongchaowart N, Sweetenham J. Intracerebral Hodgkin's lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma: a case report and literature review. Cancer Invest. 2009 Feb;27(2):215-220. Pubmedid: 19235595.
  • Almhanna K, Kim R. Second-line therapy for gemcitabine-refractory pancreatic cancer: is there a standard?. Oncology (Williston Park). 2008 Sep;22(10):1176-1183. Pubmedid: 18935928.
  • Saif MW, Hashmi S, Zelterman D, Almhanna K, Kim R. Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review. Int J Colorectal Dis. 2008 Feb;23(2):139-145. Pubmedid: 17909820.
  • Almhanna K, Pelley RJ, Thomas Budd G, Davidson J, Moore HC. Subcutaneous implantable venous access device erosion through the skin in patients treated with anti-vascular endothelial growth factor therapy: a case series. Anticancer Drugs. 2008 Feb;19(2):217-219. Pubmedid: 18176119.
  • Almhanna K, Kalmadi S, Pelley R, Kim R. Neoadjuvant therapy for hepatocellular carcinoma: is there an optimal approach?. Oncology (Williston Park). 2007 Aug;21(9):1116-1122. Pubmedid: 17910314.
  • Almhanna K, Khan P, Schaldenbrand M, Momin F. Sideroblastic anemia after bariatric surgery. Am J Hematol. 2006 Feb;81(2):155-156. Pubmedid: 16432847.
  • Chavez JC, Almhanna K, Berti-Mattera LN. Transient expression of hypoxia-inducible factor-1 alpha and target genes in peripheral nerves from diabetic rats. Neurosci Lett. 2005 Feb;374(3):179-182. Pubmedid: 15663958.
  • Almhanna K, Palanichamy N, Sharma M, Hobbs R, Sil A. Unilateral brachial plexopathy associated with West Nile virus meningoencephalitis. Clin Infect Dis. 2003 Jun;36(12):1629-1630. Pubmedid: 12802774.
  • Almhanna K, Wilkins PL, Bavis JR, Harwalkar S, Berti-Mattera LN. Hyperglycemia triggers abnormal signaling and proliferative responses in Schwann cells. Neurochem Res. 2002 Nov;27(11):1341-1347. Pubmedid: 12512939.
  • Berti-Mattera LN, Harwalkar S, Hughes B, Wilkins PL, Almhanna K. Proliferative and morphological effects of endothelins in Schwann cells: roles of p38 mitogen-activated protein kinase and Ca(2+)-independent phospholipase A2. J Neurochem. 2001 Dec;79(6):1136-1148. Pubmedid: 11752055.
  • Berti-Mattera LN, Wilkins PL, Harwalkar S, Madhun Z, Almhanna K, Mattera R. Endothelins regulate arachidonic acid release and mitogen-activated protein kinase activity in Schwann cells. J Neurochem. 2000 Dec;75(6):2316-2326. Pubmedid: 11080183.